Introduction
Adoptive T cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TILs) or T cells redirected to the tumor by chimeric antigen receptors (CARs) can mediate substantial regression of human cancers (1) . Whilst multiple early-phase studies using ACT have demonstrated durable responses which correlate with persistence of the transferred T cells (2, 3) , their in vivo activity and potency can be thwarted by the complex immunosuppressive nature of the tumor microenvironment (4) . Combination protocols incorporating checkpoint inhibitors (CPIs) such as anti-CTLA-4 or anti-PD-L1/PD-1 are currently being considered (NCT02408861; NCT02210117; NCT02374242; NCT02453620) but the potential exacerbation of the toxicities associated with CPIs may limit their implementation. Advanced genetic engineering of the ACT product offers a solution to the toxicity issues by specifically targeting tumor-reactive T cells rather than inducing systemic blockade of the inhibitory checkpoint. The protocols used for the generation of ACT are compatible with genetic manipulation of cells prior to transfer, which can be used to increase the proliferative capacity of lymphocytes (5) , to prolong their in vivo persistence (6) , to improve tumor infiltration (7) as well as to bypass tumor immune suppression.
Programmed Death-1 (PD-1, CD279) is one of the key co-inhibitory immune receptors expressed by activated T cells. Initially described on a T cell hybridoma undergoing cell death (8) , PD-1 is a critical regulator of T cell responses and essential to the maintenance of peripheral self-tolerance (9) . In mouse and human cancers, high levels of PD-1 are found on TILs, whilst its ligand (PD-L1) is upregulated by tumor and stromal cells in response to inflammatory cytokines (e.g. IFN-γ (10, 11). The PDL-1/PD-1 axis plays a major role in tumor growth and immune escape through inhibition of T cell proliferation, effector function (12) and of T cell survival by promotion of apoptosis (13) . The administration of blocking anti-PD-1 or PDL-1 antibodies in vivo results in enhanced CD8 + T cell responses and decreases tumor burden in mouse models of cancer (14, 15) . In humans, expression of PD-1 by TILs is associated with impaired effector function and/or poor outcome in several tumor types (16, 17) . Direct evidence supporting the importance of this pathway in modulating antitumor immunity comes from recent clinical trials in melanoma and non small cell lung cancer, where anti-PD-1 antibodies have improved both progression free and overall survival (18, 19 
TALEN construction and validation
Three pairs of TALEN targeting the PD-1 murine gene were produced by Cellectis using the solid phase assembly method (21) . Their activity was evaluated in 5x10 6 EL4 cells, co-transfected with 10 μg of in vitro transcribed mRNA (mMESSAGE mMACHINE T7 Kit, Ambion) from each half TALEN (Fig. S1 ). Three days post transfection, locus specific PCRs were performed on genomic DNA. (Table S1 ), mutations were assessed by mismatches digestion (T7) and Miseq analysis (20) .
Cell culture and adoptive transfer
Splenocytes and lymph nodes cells from pmel-1/SJL transgenic mice were cultured in complete RPMI with gp100 peptide (Pepceuticals) and rhIL-2 (Preprotech) 100UI/mL for 24h prior to selection of CD8 + T cells using Dynabeads FlowComp Mouse CD8
kit. TRL were selected from 100-150mm 3 tumors using Dynabeads FlowComp Mouse Pan T (CD90.2) and maintained in complete RPMI with rhIL-2 (1000UI/mL). 5x10 
Western blot analysis
Proteins were separated and subjected to the following antibodies: anti-TALEN (1mg/ml), anti-GAPDH (D16H11) (Cell signaling, 1:2000), HRP-coupled secondary antibody anti-Rabbit IgG1 HRP-linked (Cell signaling).
Statistical analysis
One-way ANOVA, two-way ANOVA or t tests with P < 0.05 were performed using Prism 6.0 software (GraphPad). Multiple comparisons were corrected with the Bonferroni coefficient and Kaplan-Meier survival curves were compared with the logrank test.
For additional information, see supplemental data section

Results and Discussion
TALEN-mediated PD-1 gene inactivation in melanoma reactive CD8 + pmel-1 T cells increases persistence of CD8 PD-1Ex1 pmel-1 cells at the tumor site
Three pairs of TALENs targeting the murine PD-1 gene were tested in EL4 cells using an optimized mRNA-electroporation protocol. Only the pair targeting the exon 1 sequence (Fig. 1A) caused detectable mismatch-identified mutagenesis (up to 27%) in the PD-1 gene, correlating with loss of PD-1 expression in up to 15% of electroporated EL4 cells (Supplementary Fig. S1 ). To investigate whether PD-1 inactivation of primary tumor-reactive T cells provided superior antitumor activity against the poorly immunogenic mouse melanoma B16 model, we used CD8 + T cell receptor transgenic (TCR Tg) cells specific to the melanoma differentiation antigen gp-100 (pmel-1, Supplementary Fig. S2A ) (22) . In vitro activated pmel-1 T cells were electroporated with control GFP mRNA (CD8 wt ) or PD-1-targeting TALEN mRNA (CD8 PD-1Ex1 ), delivering a high transfection efficiency of >85% as confirmed by GFP expression (Supplementary Fig. S2B ). Western blot analysis confirmed transient TALEN expression one day (d1) after transfection (Fig.1B) and Miseq analysis of the targeted sequence showed a high frequency of mutations (53% non-homologous end joining (NHEJ)) (Fig. 1C) . Three days after transfection, PD-1 negative cells were enriched using magnetic beads (Supplementary Fig. S2C ) prior to ACT of 1x10 6 CD8 wt or CD8 PD-1Ex1 pmel-1 cells and rhIL-2 into B16 tumor-bearing mice.
Significantly enhanced tumor control was consistently observed in mice receiving CD8 PD-1Ex1 cells compared to those treated with CD8 wt cells (Fig. 1D) . Six days after transfer in vivo, a significant enrichment of tumor-infiltrating PD-1 negative pmel-1 cells was observed in mice treated with CD8 PD-1Ex1 T cells (48.2%) (Fig. 1E upper   panel) , which contributed to a 2-fold increase in the total number of tumor-infiltrating pmel-1 cells (Fig. 1E lower panel) . In contrast,, the absolute number of T cells in draining lymph nodes (DLNs) was similar between the two groups, suggesting that accumulation of CD8 PD-1Ex1 T cells at the tumor site was not due to differences in engraftment nor infiltration from the DLNs (Supplementary Fig. S2D ). Whereas use of RNA and electroporation to deliver TALENs is compatible with future clinical translation, it does not allow incorporation of a reporter gene to distinguish PD-1 edited cells. Nevertheless, the rate of mutagenesis, investigated ex-vivo 7 days after ACT demonstrates an effective PD-1 gene editing (70%) in the PD-1 negative fraction from the CD8 PD-1Ex1 group (Supplementary Fig. S2E ). (Supplementary Fig. S2F, G, H) . Instead, we consistently observed the appearance of a PD-1 -pmel-1 population in the CD8 PD-1Ex1 group, which contributed to an increase in the total number of KI67-, GZB-and IFN-γ -expressing cells in tumors from mice receiving CD8 PD-1Ex1 T cells (Fig. 1F, G Fig. S3A, B) .
In parallel to the generation of the donor mock transfected (TRL wt ) and PD-1 edited Fig. 2A, B) . Consistent with our findings in the TCR Tg model, a significant accumulation of PD-1 -cells was observed only at the tumor site (Fig. 2C, S3C ). Whilst PD-1 gene inactivation did not alter TRL proliferation (KI67) or function (GZB and IFN-γ) (Supplementary Fig.   S3D , E, F), the absolute number of PD1 -TRL expressing KI67, GZB and IFN-γ was significantly higher in mice receiving TRL PD-1EX1 (Fig. 2D, E, F) .
Given that the increase in the number of PD-1 -cells in mice receiving TRL PD-1EX1 cells was not associated with increased proliferation, we evaluated whether this could be explained by a reduced rate of PD-1-induced death. Using annexin-V and a fluorescent caspase substrate kit (FLICA), we observed an overall reduction in the frequency of intra-tumoral apoptotic cells in PD-1 -compared to PD-1 + CD4 + and CD8 + T cells (Fig. 3A, B, D, E) . Whereas we observed no difference in the frequency of apoptotic cells between mice treated with TRL wt and TRL PD-1EX1 , a significant increase in the absolute number of annexin-V -and FLICA -TRL PD-1EX1 cells per mg of tumor was reported (Fig. 3C, F) . The data suggest that instead of increasing T cell reactivity against tumors, TRL PD-1EX1 cells are rendered resistant to PD-1-mediated cell death at the tumor site.
PD-1 gene-inactivation drives CD4 and CD8 dependent rejection of established tumors and long-term memory
PD-1-gene inactivation significantly increased the activity of our ACT protocol (p=0.0052) and anti-tumor activity was dependent on both CD8 + and CD4 + T cells as administration of depleting anti-CD8 or MHC-II blocking antibodies ablated antitumor responses (Fig. 4A, B) . No evidence of tumor recurrence was observed after MCA205 rechallenge on day 50 in mice that had previously rejected tumors (data not shown). The development of long-term memory, as demonstrated by protection against a subsequent tumor challenge, is an important feature of successful T cell adoptive immunotherapy (25) . Our data show high levels of KI67, consistent with high proliferative capacity for both TRL and TRL PD-1EX1 cells, which also displayed a Fig. S4A,B ) (27) . Finally, ex-vivo stimulation of circulating T cells from surviving mice (40 days after tumor rejection) demonstrated high levels of IFN- production in both TRL and TRL PD-1EX1 groups arguing against terminal differentiation ( Supplementary Fig. S4C ) (28) . 
P<0.01. (B)
Treatment with TRL PD-1Ex1 resulted in significant prolongation of survival (n=15).
Log-rank test, P=0.0052. Depletion of CD8 + subset or MHC-II blockade abrogates the TRL PD-1Ex1 cells-induced antitumor effects (n=10).
